
STATUTORY INSTRUMENTS

2014 No. 3276

DANGEROUS DRUGS, ENGLAND AND WALES
DANGEROUS DRUGS, SCOTLAND

The Misuse of Drugs (Designation) (Amendment)
(No. 3) (England, Wales and Scotland) Order 2014

Made - - - - *11th December 2014*
Laid before Parliament *17th December 2014*
Coming into force - - *7th January 2015*

The Secretary of State, in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971⁽¹⁾, and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act, makes the following Order:

Citation, commencement and extent

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment) (No. 3) (England, Wales and Scotland) Order 2014 and comes into force on 7th January 2015.

(2) This Order extends to England and Wales and Scotland.

Amendment to the Misuse of Drugs (Designation) Order 2001

2.—(1) The Misuse of Drugs (Designation) Order 2001⁽²⁾ is amended as follows.

(2) In paragraph 1(a) of Part 1 of the Schedule—

(a) after “Tenocyclidine” insert—

“(6a*R*,9*R*)-4-acetyl-*N,N*-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ALD-52)”;

(b) after “4-Bromo-2,5-dimethoxy-*a*-methylphenethylamine” insert—

“3,4-dichloro-*N*-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)
(6a*R*,9*R*)-*N,N*-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (AL-LAD)

⁽¹⁾ 1971 c. 38.

⁽²⁾ S.I. 2001/3997 as amended by S.I. 2005/1652, S.I. 2009/3135, S.I. 2010/1143, S.I. 2010/1800, S.I. 2011/447, S.I. 2012/1310, S.I. 2013/177, S.I. 2013/624, S.I. 2014/1274 and S.I. 2014/1376.

(6a*R*,9*R*)-*N,N*-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ETH-LAD)

(6a*R*,9*R*)-*N,N*-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (PRO-LAD)”;

(c) after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“2,4-dimethylazetidinyll{(6a*R*,9*R*)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinolin-9-yl}methanone (LSZ)”.

(3) For paragraph 1(b) of Part 1 of the Schedule, substitute—

“(b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;”.

Lynne Featherstone
Minister of State
Home Office

11th December 2014

EXPLANATORY NOTE

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order 2001 by inserting the synthetic opiate (known as AH-7921) and LSD related compounds into Part 1 of the Schedule to that Order. This Order also replaces the definition of tryptamine compounds in Part 1 of the Schedule with a wider generic definition.

A full impact assessment of the effect that this instrument will have on the costs of business and the voluntary sector is available and is published with the Explanatory Memorandum alongside the instrument on www.legislation.gov.uk.